title: Hematopoietic cell proliferation and hematopoietic growth factors.
abstract: In vivo studies using hematopoietic growth factors in humans have more clearly defined the ability of these molecules to accelerate hematopoietic cell proliferation in postchemotherapy aplasia and constitutive marrow deficiency states. Studies applying combinations of two growth factors have been added. Investigation of negative regulators of hematopoietic cell proliferation has opened new approaches to protect against damage or loss of candidate stem cells in vitro or in vivo, as well as to selectively recruit malignant cell populations into cell cycle while protecting benign cells. New insights into the synergism of positive regulators of hematopoietic cell proliferation have come from a panoply of in vitro studies, underscoring the value of growth factors previously not associated with effects on hematopoietic cells that have now been found to confer significant synergism with known hematopoietic regulators.
authors.affiliation: Albert-Ludwigs University, Freiburg, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Weber-Nordt
authors.forename: R
authors.initials: R
authors.lastname: Mertelsmann
authors.forename: R
authors.initials: R
authors.lastname: Henschler
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D006133:Growth Substances / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D019653:Myeloablative Agonists
chemical_list: D000970:Antineoplastic Agents; D006133:Growth Substances; D016298:Hematopoietic Cell Growth Factors; D019653:Myeloablative Agonists